Exchange: NASDAQ·Updated 07:55 PM EST

MEDP News

News
all
press releases
Medpace (MEDP) Down 3.1% Since Last Earnings Report: Can It Rebound?
Medpace (MEDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Medpace (MEDP) Down 3.1% Since Last Earnings Report: Can It Rebound?
Medpace (MEDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
CON vs. MEDP: Which Stock Is the Better Value Option?
Zacks
Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) have been assigned an average recommendation of "Hold" from the thirteen analysts that are currently covering the company, MarketBeat Ratings reports. Ten research analysts have rated the stock with a hold rating and three have given a...
MarketBeat
Investors need to pay close attention to MEDP stock based on the movements in the options market lately.
Zacks
Mawer Investment Management Ltd. cut its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 80.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,031 shares of the company's stock af...
MarketBeat
Here is how Medpace (MEDP) and Atea Pharmaceuticals, Inc. (AVIR) have performed compared to their sector so far this year.
Zacks
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks
Alcon's Q3 earnings top estimates as sales miss, margins expand and 2026 growth targets narrow; shares slip after the report.
Zacks
Natera???s Q3 revenues jump 34.1%, beating estimates, while a wider-than-expected loss and surging oncology test volumes shape its raised 2026 sales outlook.
Zacks
Bio-Techne's Q1 fiscal 2027 earnings and revenues beat estimates, driven by Protein Sciences growth, as its merger with Merck KGaA moves closer to completion.
Zacks

Advertisement|Remove ads.